This communication contains certain forward-looking statements concerning the MorphoSys group of companies, The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties, Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated, MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.For more information, please contact: MorphoSys AG Anke LinnartzHead of Corporate Communications & IR Alexandra GollerSenior Manager Corporate Communications & IR Jochen OrlowskiAssociate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-404 email@example.com Attachments: http://www.globenewswire.com/NewsRoom/AttachmentNg/9c5f0038-2072-4506-a5a7-bee39d75c583
MARTINSRIED / MUNICH, Germany, Nov. 14, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences: Bryan Garnier 4th Healthcare ConferenceDate: November 14, 2016Venue: Paris, FrancePresenter: Dr. Claudia Gutjahr-Löser & Anke LinnartzHead of Corporate Communications & IR HSBC Healthcare Day 2016Date: November 17, 2016Venue: Frankfurt, GermanyPresenter: Jens Holstein, Chief Financial Officer of MorphoSys AGAnke Linnartz, Head of Corporate Communications & IR Eigenkapitalforum 2016Date: November 21, 2016Venue: Frankfurt, GermanyPresenter: Jens Holstein, Chief Financial Officer of MorphoSys AGAnke Linnartz, Head of Corporate Communications & IR 13th Kempen & Co Life Sciences ConferenceDate: November 23, 2016Venue: London, UKPresenter: Jens Holstein, Chief Financial Officer of MorphoSys AGAnke Linnartz, Head of Corporate Communications & IR dbAccess Pharmaceutical & Healthcare Corporate DayDate: December 1, 2016Venue: London, UKPresenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AGAnke Linnartz, Head of Corporate Communications & IR American Society of Hematology (ASH) Annual Meeting 2016Date: December 5, 2016MorphoSys will hold an Investor & Analyst Event at the 2016 ASH Annual Meeting. Clinical data published at the medical conference will be presented. A PDF version of all presentations will be provided at www.morphosys.com. The link to webcasts will be filed under www.morphosys.com/conference-calls. About MorphoSys:MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com. HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.